吲哚瑞酯

吲哚瑞酯
识别信息
	IUPAC命名法 methyl 3-amino-2-(5-methoxy-1H-indol-3-yl)propanoate; ;
CAS号	73758-06-2
PubChem CID	71987;
ChemSpider	64989 ;
UNII	AV9L041QA4;
CompTox Dashboard（英语：CompTox Chemicals Dashboard） (EPA)	DTXSID2048400 ;
化学信息
化学式	C13H16N2O3
摩尔质量	248.277 g/mol
3D模型（JSmol（英语：JSmol））	交互式图像;
	SMILES COC(=O)C(CN)c1cnc(ccc2OC)c1c2;

吲哚瑞酯（英語：Indorenate，TR-3369）是一种色胺衍生物，常作为5-HT_1A（英语：5-HT1A receptor）、5-HT_1B（英语：5-HT1B receptor）、5-HT_2C（英语：5-HT2C receptor）等血清素受体的激动剂。它具有抗焦虑、降压和降食欲（英语：anorectic）的作用，主要是通过激动5-HT_1A受体来完成，但5-HT_1B和5-HT_2C也有可能起一定作用，另外一些非血清素受体也可能是它的靶标。^[1]^[2]^[3]^[4]^[5]^[6]^[7]^[8]^[9]

事实速览 识别信息, CAS号 ...

关闭

另见

5-甲氧基色胺

参考文献

[1]
Antonaccio MJ, Kerwin L. On the effects and mechanism of action of the antihypertensive agent TR 3369 (5-methoxytryptamine beta-methylcarboxylate) in spontaneously hypertensive rats. Journal of Cardiovascular Pharmacology. 1981, 3 (6): 1306–11. PMID 6173531.
[2]
Schoeffter P, Hoyer D. Centrally acting hypotensive agents with affinity for 5-HT1A binding sites inhibit forskolin-stimulated adenylate cyclase activity in calf hippocampus. British Journal of Pharmacology. November 1988, 95 (3): 975–85. PMC 1854240 . PMID 3207999.
[3]
Fernández-Guasti A, Escalante A, Hong E, Agmo A. Behavioural actions of the serotonergic anxiolytic indorenate. Pharmacology, Biochemistry, and Behavior. September 1990, 37 (1): 83–8. PMID 1979877. doi:10.1016/0091-3057(90)90045-J.
[4]
López Cabrera M, Velázquez Martínez DN, Prado R, García G, Ortiz R. Effects of the intracerebroventricular administration of indorenate and fenfluramine on spontaneous behavior and food intake in rats. Proceedings of the Western Pharmacology Society. 1991, 34: 465–8. PMID 1788330.
[5]
Velázquez-Martínez DN, López Cabrera M, Sánchez H, Ramírez JI, Hong E. Discriminative stimulus properties of indorenate, a serotonin agonist. Journal of Psychiatry & Neuroscience : JPN. March 1999, 24 (2): 122–30. PMC 1188992 . PMID 10212554.
[6]
Sánchez H, Velázquez-Martínez DN. Discriminative stimulus properties of indorenate, a 5-HT1A, 5-HT1B and 5-HT2C agonist: a study in rats. Journal of Psychopharmacology (Oxford, England). March 2001, 15 (1): 29–36. PMID 11277605.
[7]
Miranda F, Orozco G, Velázquez-Martínez DN. Full substitution of the discriminative cue of a 5-HT(1A/1B/2C) agonist with the combined administration of a 5-HT(1B/2C) and a 5-HT(1A) agonist. Behavioural Pharmacology. July 2002, 13 (4): 303–11. PMID 12218511.
[8]
Miranda F, Hong E, Sánchez H, Velázquez-Martínez DN. Further evidence that the discriminative stimulus properties of indorenate are mediated by 5-HT 1A/1B/2C receptors. Pharmacology, Biochemistry, and Behavior. January 2003, 74 (2): 371–80. PMID 12479957. doi:10.1016/S0091-3057(02)01010-9.
[9]
López-Meraz ML, Neri-Bazán L, Rocha L. Indorenate modifies a1-adrenergic and benzodiazepine receptor binding in the rat brain: an autoradiography study. The Journal of Pharmacy and Pharmacology. September 2006, 58 (9): 1243–8. PMID 16945183. doi:10.1211/jpp.58.9.0011.

[pmid6173531-1] [1]
Antonaccio MJ, Kerwin L. On the effects and mechanism of action of the antihypertensive agent TR 3369 (5-methoxytryptamine beta-methylcarboxylate) in spontaneously hypertensive rats. Journal of Cardiovascular Pharmacology. 1981, 3 (6): 1306–11. PMID 6173531.

[pmid3207999-2] [2]
Schoeffter P, Hoyer D. Centrally acting hypotensive agents with affinity for 5-HT1A binding sites inhibit forskolin-stimulated adenylate cyclase activity in calf hippocampus. British Journal of Pharmacology. November 1988, 95 (3): 975–85. PMC 1854240 . PMID 3207999.

[pmid1979877-3] [3]
Fernández-Guasti A, Escalante A, Hong E, Agmo A. Behavioural actions of the serotonergic anxiolytic indorenate. Pharmacology, Biochemistry, and Behavior. September 1990, 37 (1): 83–8. PMID 1979877. doi:10.1016/0091-3057(90)90045-J.

[pmid1788330-4] [4]
López Cabrera M, Velázquez Martínez DN, Prado R, García G, Ortiz R. Effects of the intracerebroventricular administration of indorenate and fenfluramine on spontaneous behavior and food intake in rats. Proceedings of the Western Pharmacology Society. 1991, 34: 465–8. PMID 1788330.

[pmid10212554-5] [5]
Velázquez-Martínez DN, López Cabrera M, Sánchez H, Ramírez JI, Hong E. Discriminative stimulus properties of indorenate, a serotonin agonist. Journal of Psychiatry & Neuroscience : JPN. March 1999, 24 (2): 122–30. PMC 1188992 . PMID 10212554.

[pmid11277605-6] [6]
Sánchez H, Velázquez-Martínez DN. Discriminative stimulus properties of indorenate, a 5-HT1A, 5-HT1B and 5-HT2C agonist: a study in rats. Journal of Psychopharmacology (Oxford, England). March 2001, 15 (1): 29–36. PMID 11277605.

[pmid12218511-7] [7]
Miranda F, Orozco G, Velázquez-Martínez DN. Full substitution of the discriminative cue of a 5-HT(1A/1B/2C) agonist with the combined administration of a 5-HT(1B/2C) and a 5-HT(1A) agonist. Behavioural Pharmacology. July 2002, 13 (4): 303–11. PMID 12218511.

[pmid12479957-8] [8]
Miranda F, Hong E, Sánchez H, Velázquez-Martínez DN. Further evidence that the discriminative stimulus properties of indorenate are mediated by 5-HT 1A/1B/2C receptors. Pharmacology, Biochemistry, and Behavior. January 2003, 74 (2): 371–80. PMID 12479957. doi:10.1016/S0091-3057(02)01010-9.

[pmid16945183-9] [9]
López-Meraz ML, Neri-Bazán L, Rocha L. Indorenate modifies a1-adrenergic and benzodiazepine receptor binding in the rat brain: an autoradiography study. The Journal of Pharmacy and Pharmacology. September 2006, 58 (9): 1243–8. PMID 16945183. doi:10.1211/jpp.58.9.0011.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]